Weiming Penguin Invited to the 2024 Pharmaceutical Distribution Innovation Conference and Wins “Digital Transformation Benchmark Case Award” | Weiming Honors
Article images may contain Chinese text.
On September 12, 2024, the “2024 Pharmaceutical Distribution Innovation Conference and China Pharmaceutical Distribution Industry Information Conference” opened in Dalian. Held under the guidance of the Department of Market Operation and Consumption Promotion of China’s Ministry of Commerce, the event was hosted by the China Association of Pharmaceutical Commerce and co-organized by its Innovative Drug Distribution Branch, Pharmaceutical Market Research Committee, and Digital and Intelligent Applications Branch.


To implement the Ministry of Commerce’s “Guiding Opinions on Promoting High-Quality Development of the Pharmaceutical Distribution Industry During the 14th Five-Year Plan Period” and advance digital transformation and high-quality development in the pharmaceutical distribution industry, the China Association of Pharmaceutical Commerce organized a call for “2024 National Innovative Cases of Digital Transformation in the Pharmaceutical Industry.”
Following multiple rounds of selection, including company submissions, the association’s preliminary review, expert evaluation, and online voting, Weiming Penguin won the highest honor—the “Digital Transformation Benchmark Case Award”—for its case study, “The DIG Smart Digital and Intelligent Solution Matrix Leads a New Chapter in the Pharmaceutical Industry’s Digital Transformation”!


At the Sixth Pharmaceutical Big Data Applications Forum and Second Pharmaceutical Industry Artificial Intelligence Applications Conference held on September 13, Dr. Zou Xiaoliang, founder and CEO of Weiming Penguin, delivered an engaging speech titled “New Ways of Working in the AI Era.”

Using internet companies as examples, he discussed how data governance and networked collaboration can drive business innovation and development. Mr. Zou Xiaoliang identified three keys to business success: first, focusing on customer needs; second, continually optimizing strategy; and third, maintaining a sense of urgency and a spirit of innovation. He emphasized that Weiming Penguin is committed to providing the pharmaceutical industry with more intelligent and precise services through the in-depth application of AI and big data technologies.

In terms of data, Weiming Penguin’s work focuses on three areas. First, data collection and cleansing: using machine learning technologies to extract and cleanse data from more than 10,000 pharmaceutical distributors to ensure data accuracy and efficiency. Second, developing algorithm-based products to provide data insights: analyzing information such as customers’ distributors and the market potential of their products to provide customers with more precise business decision support. Third, master data management and customer relationship management: using digital tools to help customers manage their businesses in real time, addressing problems such as incomplete data samples and the inability to view data promptly.
In addition, Ms. Tian Ying, co-founder and president of Weiming Penguin, shared her distinctive insights at the roundtable “High-Level Dialogue: Empowering High-Quality Development of the Pharmaceutical Industry Through Digital and Intelligent Technologies.”

Guided by its mission of “Connecting Health,” Weiming Penguin is committed to building a digital ecosystem for the pharmaceutical and healthcare industry, providing big data products and digital solutions to help pharmaceutical companies achieve data-driven business growth.
This year marks Weiming Penguin’s ninth year since its founding. Its founding team has spent decades working in the pharmaceutical industry and has a deep understanding of the policy environment and operational pain points. Through AI+Data digital tools and professional services, Weiming Penguin will continue helping the pharmaceutical industry push beyond efficiency boundaries and find new growth curves.
